Weekly update|Companies|Recruiting|Promote|Post a job

Vera Therapeutics

Founded: 2017

Location: Brisbane, CA

Employee range: 11 - 50

Clinical stage: Clin3

Therapy area: Lupus nephritis

Drug types: IMM, NPH, INF

Lead product: Atacicept

Product link: https://veratx.com/atacicept/

Funding: $115M stock Feb 2023; $48M IPO May 2021; $80M C Jan 2021; $34M Sep 2019

veratx.com

linkedin.com

job board

Short description:

Gene Editing Technology

Drug notes:

Also Clin2b IgA nephropathy; MAU868 Clin2 BK viremia in renal transplant, Clin0 BKV cystitis in HSCT

Long description:

Vera Therapeutics late-stage biotech company focuses on developing treatments for serious immunological, inflammatory, and rare diseases such as nephropathy. They aim to not only treat symptoms, but target the source of disease through modulation of the immune system in order to transform the standard of care for these patients. This approach could not only halt disease, but has the potential for reversal of the disease. For example, through the inhibition of cytokines, B- cells are prevented from producing disease-causing antibodies that result in kidney disease. Overall, Vera is dedicated to addressing diseases that may be altered by the inhibition of autoantibody development, while keeping sustainability in mind.